We demonstrate that biphasic SS contains a variety of lymphocyte subsets (CD4+ helper T cells, CD8+ cytotoxic T cells, and B cells), which may justify the use of neoadjuvant chemotherapy and/or immunotherapy specifically for biphasic SS. This evidence concerns the gene CD8A and synovial sarcoma.